Recombinant Human 4-1BB/TNFRSF9 Protein, >90% (SDS-PAGE), high purity

Item Number

rp169624

• Product Name: Recombinant Human 4-1BB/TNFRSF9 Protein, >90% (SDS-PAGE), high purity
• Grade: ActiBioPure™, Animal Free, Azide Free, Bioactive, Carrier Free
• Specifications & Purity: ActiBioPure™, Bioactive, Animal Free, Carrier Free, Azide Free, ≥90%(SDS-PAGE)
• Purity: >90% (SDS-PAGE)
• Bioactivity: Measured by its binding ability in a functional ELISA. Human 4-1BB/TNFRSF9 (rp169624) at 1.0 μg/mL can bind Urelumab (anti-TNFRSF9) (Ab170654) with the EC50 of 47.08 ng/mL.
• Endotoxin Concentration: <1 EU/μg
• Expression System: HEK293
• Amino Acids: 1-186 aa
• Sequence: MGNSCYNIVATLLLVLNFERTRSLQDPCSNCPAGTFCDNNRNQICSPCPPNSFSSAGGQRTCDICRQCKGVFRTRKECSSTSNAECDCTPGFHCLGAGCSMCEQDCKQGQELTKKGCKDCCFGTFNDQKRGICRPWTNCSLDGKSVLVNGTKERDVVCGPSPADLSPGASSVTPPAPAREPGHSPQHHHHHH
• Protein Tag: C-His
• Predicted molecular weight: 18.1 kDa
• SDS-PAGE: 27.8-38.6 kDa, under reducing conditions; 28.4-37.9 kDa, under non-reducing conditions

Product Description

Purity:>90%, by SDS-PAGE visualized with Coomassie® Blue Staining.
Description：
CD137 (also known as 4-1BB) is a surface co-stimulatory glycoprotein originally described as present on activated T lymphocytes, which belongs to the tumor necrosis factor (TNF) receptor superfamily. It is expressed mainly on activated CD4+ and CD8+ T cells, and binds to a high-affinity ligand (4-1BBL) expressed on several antigen-presenting cells such as macrophages and activated B cells. Upon ligand binding, 4-1BB is associated with the tumor necrosis factor receptor–associated factors (TRAFs), the adaptor protein which mediates downstream signaling events including the activation of NF-kappaB and cytokine production. 4-1BB signaling either by binding to 4-1BBL or by antibody ligation delivers signals for T-cell activation and growth, as well as monocyte proliferation and B-cell survival, and plays an important role in the amplification of T cell-mediated immune responses. In addition, CD137 and CD137L are expressed in different human primary tumor tissues, suggesting that they may influence the progression of tumors. Crosslinking of CD137 on activated T cells has shown promise in enhancing anti-tumor immune responses in murine models, and agonistic anti-CD137 antibodies are currently being tested in phase I clinical trials. Soluble forms of CD137 (sCD137) are generated by differential splicing. sCD137 can bind to CD137 ligand to antagonize the costimulatory activities of the membrane-bound CD137 and reduce T cell proliferation and IL-2 secretion.